(Total Views: 5090)
Posted On: 04/12/2017 10:21:44 AM
Post# of 1086
$PMCB voting 2393 / PharmaCyte Biotech PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) to protect its therapy to treat cancerous tumors, including the therapy that will be used in its upcoming clinical trial in locally advanced pancreas cancer (LAPC). 3 reasons to vote for us: 1. a new kind of Chemo without side effects
2. a new treatment for Pancreatic Cancer
3. a chance to give a person that is dying a better quality of life and a chance to live - See more at: http://convention.bio.org/buzzofbio/voting.aspx#votethankyou
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) to protect its therapy to treat cancerous tumors, including the therapy that will be used in its upcoming clinical trial in locally advanced pancreas cancer (LAPC). 3 reasons to vote for us: 1. a new kind of Chemo without side effects 2. a new treatment for Pancreatic Cancer
3. a chance to give a person that is dying a better quality of life and a chance to live - See more at: http://convention.bio.org/buzzofbio/voting.aspx#votethankyou
(0)
(0)
